← FDA DRUG APPROVALS

FDA ANDA · ANDA075853

DILTIAZEM HYDROCHLORIDE

Sponsor: HOSPIRA

APPLICATION
ANDA075853
TYPE
ANDA
ORIGINAL APPROVAL
2002-12-17
LATEST ACTION
2017-12-13
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DILTIAZEM HYDROCHLORIDEPrescription
DILTIAZEM HYDROCHLORIDE 100MG/VIAL · INJECTABLE · INJECTION

Approval history

2017-12-13Labeling · Supplement 9 · standardAP
2007-01-03Labeling · Supplement 3AP
2002-12-17OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →